Skip to main content
Premium Trial:

Request an Annual Quote

IMC Selects Expression Analysis for Microarray Processing Services

NEW YORK, June 8 (GenomeWeb News) - IMC selected Expression Analysis for microarray processing services to support its clinical trial on drug addiction, Expression Analysis said today.

The Durham, NC-based company will isolate genomic samples and analyze those on both gene-expression and genotyping microarrays. The samples are from a clinical trial IMC is conducting.
The clinical trial is funded through an award received last year from the National Institute on Drug Abuse. The trial uses IMC's TeraGenomics, a data warehousing product to manage, analyze and share Affymetrix GeneChip microarray data to analyze the effectiveness of a compound used to treat methamphetamine addiction.
Financial details were not disclosed.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.